BioStem Technologies

Florida-based BioStem Technologies, Inc. (OTCMKTS: BSEM) is a biotech company focused on developing and manufacturing structural-tissue allografts derived from perinatal tissues and intended for use as a protective covering for soft-tissue wounds.  Perinatal tissue – an abundant source...

Jason Matuszewski, CEO and co-founder of BioStem Technologies, Inc. (OTCMKTS: BSEM), presented at last year’s Dawson James Small Cap Growth Conference in October. BioStem is a biotech company developing tissue allografts from perinatal tissue — including umbilical cords, and placentas...

Benzinga recently spoke to the CEO of BioStem Technologies, Inc. (OTCMKTS: BSEM) (“BioStem”), Jason Matuszewski, about his company’s mission and future.  BioStem is a leading biotech innovator focused on harnessing the natural properties of perinatal tissue to help patients...

BioStem Technologies, Inc. (OTCQB: BSEM) is a Florida-based biotechnology company focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of structural tissue allografts for use as a protective covering for soft-tissue wounds. The year...

The human body has an amazing ability to heal itself, but the pace and extent of healing can vary dramatically from case to case, depending on the nature of the injury, site and the extent of tissue damage.  The terms regenerative medicine and tissue engineering —where the body uses its...

BioStem Technologies Inc. (OTCPK: BSEM) is a biotechnology company in the cutting-edge regenerative medicine field focused on harnessing elements of perinatal tissue derived from the human placenta for manufacturing structural tissue allografts to heal wounds.  Perinatal tissues are an...

The treatment of chronic and acute wounds has always represented a major challenge in the healthcare field.  Chronic wounds are defined as wounds that have failed to progress through the phases of healing in an orderly and timely fashion and have shown no significant progress toward healing in...

An allograft is tissue that is transplanted from one person to another. The prefix “allo” comes from a Greek word meaning “other.” An allograft is different from an autograft, which uses the individual's own tissue and is, therefore, genetically identical. Human...

The below report was authored by Brad Sorensen, CFA, Zacks Small Cap Research. You can find the original report here.   BioStem Technologies (OTCMKTS: BSEM) is changing the skin graft market by using the natural properties of perinatal tissue. Revenues are rising and...

C O R P O R A T E   P A R T I C I P A N T S Nicolas Johnson, Russo Partners Jason Matuszewski, Chief Executive Officer Michael Fortunato, Controller C O N F E R E N C E   C A L L   P A R T I C I P A N T S Stefan Roaczek, Benzinga P R E S E N T A T I O N Operator Welcome to the...

BioStem Technologies Inc. (OTCMKTS: BSEM) is a regenerative medicine company that develops and manufactures tissue allografts for use in surgery and wound care. In August, the company reported growth exceeding even its own expectations as net revenue increased to $2.2 million for the second quarter...

Jason Matuszewski, CEO of BioStem Technologies Inc. (OTCMKTS: BSEM), was a guest speaker at Benzinga’s All Access on June 17th, 2022.  BioStem Technologies Inc. is a pre-clinical-stage biotechnology company that has developed a proprietary approach, called Local MicroEnvironment...